Repligen (NASDAQ:RGEN) Shares Gap Up to $168.07

Repligen Co. (NASDAQ:RGENGet Rating) gapped up before the market opened on Wednesday . The stock had previously closed at $168.07, but opened at $172.67. Repligen shares last traded at $174.67, with a volume of 946 shares.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. StockNews.com assumed coverage on Repligen in a report on Thursday, March 31st. They set a “hold” rating on the stock. UBS Group assumed coverage on Repligen in a report on Wednesday. They set a “buy” rating and a $213.00 price target on the stock. Finally, Craig Hallum reduced their price target on Repligen from $286.00 to $274.00 in a report on Thursday, April 28th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $288.86.

Repligen Stock Performance

The business has a 50-day moving average of $161.00 and a 200-day moving average of $173.06. The stock has a market capitalization of $11.08 billion, a price-to-earnings ratio of 80.49 and a beta of 0.95.

Repligen (NASDAQ:RGENGet Rating) last released its earnings results on Wednesday, April 27th. The biotechnology company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.20. The company had revenue of $206.40 million during the quarter, compared to the consensus estimate of $185.48 million. Repligen had a return on equity of 11.13% and a net margin of 19.86%. Repligen’s revenue was up 44.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.68 EPS. Equities analysts predict that Repligen Co. will post 3.1 earnings per share for the current fiscal year.

Insider Buying and Selling at Repligen

In other Repligen news, Director Karen A. Dawes sold 14,715 shares of Repligen stock in a transaction dated Wednesday, May 25th. The stock was sold at an average price of $150.51, for a total value of $2,214,754.65. Following the completion of the transaction, the director now directly owns 76,532 shares of the company’s stock, valued at approximately $11,518,831.32. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Repligen

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Exchange Traded Concepts LLC grew its position in shares of Repligen by 2.3% during the second quarter. Exchange Traded Concepts LLC now owns 2,996 shares of the biotechnology company’s stock worth $487,000 after buying an additional 68 shares in the last quarter. Brinker Capital Investments LLC grew its position in shares of Repligen by 23.0% during the second quarter. Brinker Capital Investments LLC now owns 1,816 shares of the biotechnology company’s stock worth $295,000 after buying an additional 339 shares in the last quarter. Moody Aldrich Partners LLC grew its position in shares of Repligen by 855.7% during the second quarter. Moody Aldrich Partners LLC now owns 31,948 shares of the biotechnology company’s stock worth $5,188,000 after buying an additional 28,605 shares in the last quarter. Kensington Investment Counsel LLC grew its position in shares of Repligen by 90.4% during the second quarter. Kensington Investment Counsel LLC now owns 9,274 shares of the biotechnology company’s stock worth $1,506,000 after buying an additional 4,402 shares in the last quarter. Finally, Bright Rock Capital Management LLC acquired a new position in shares of Repligen during the second quarter worth about $1,462,000. 86.82% of the stock is owned by institutional investors and hedge funds.

About Repligen

(Get Rating)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Further Reading

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.